About

Committed to developing innovative solutions

Silo Pharma, Inc. (Nasdaq: SILO) is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.

The Silo difference

We are committed to developing innovative solutions to address a variety of underserved conditions including Alzheimer’s; Fibromyalgia; and Stress-Induced Psychiatric Disorders.

While partnering with some of the leading Academic Institutions Silo has licensed therapeutics that will allow the company to pursue the more streamlined 505(b)(2) route for trials.  

Silo anticipates this strategy will lower cost and allow for a faster approval process to help patients with few if any proven addressable therapeutics.

Get more information on Silo Pharma. Sign up for email alerts online.

SIGN UP